Research Articles | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Where There's Smoke, There's Fire: Inflammation Drives MDS Jul 2020 Trends in immunology Myelodysplastic Syndromes (MDS)
Epigenetic Aging and Hematopoietic Cell Transplantation in Patients With Severe Aplastic Anemia Apr 2021 Transplantation and Cellular Therapy Aplastic Anemia, Graft Versus Host Disease (GVHD)
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care Jul 2023 Transplantation and Cellular Therapy Myelodysplastic Syndromes (MDS)
Transplant Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care Apr 2023 Transplantation and Cellular Therapy Myelodysplastic Syndromes (MDS)
Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms Jul 2024 Therapeutic Advances in Hematology Myelodysplastic Syndromes (MDS)
Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria Sep 2019 Therapeutic Advances in Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Treatment options for lower-risk myelodysplastic syndromes. Where are we now? Jan 2021 Therapeutic Advances in Hematology Myelodysplastic Syndromes (MDS)
Efficacy of complement inhibitors for patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis Dec 2023 Therapeutic Advances in Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Management of myelodysplastic syndromes after failure of response to hypomethylating agents May 2019 Therapeutic Advances in Hematology Myelodysplastic Syndromes (MDS)
One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study Oct 2020 Therapeutic Advances in Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)